2026-01-10 - Analysis Report
Here's a comprehensive analysis of TransMedics Group Inc. (TMDX) based on the provided data, organized into the requested sections:

**0) Report and Analysis Structure:**

*   First, I present the raw numbers as provided.
*   Then, I provide a simple analysis of those numbers, focusing on key takeaways.

**1) Return Rate Comparison (TMDX vs. S&P 500)**

*   **Ticker:** TMDX
*   **Company Name:** Transmedics Group Inc
*   **Company Overview:**  TransMedics is a medical technology company focused on developing and delivering organ preservation systems for transplantation.
*   **TMDX Cumulative Return:** 235.64%
*   **VOO (S&P 500) Cumulative Return:** 72.50%
*   **Divergence:**
    *   Max: 250.8
    *   Min: -71.8
    *   Current: 128.7
    *   Relative Divergence: 62.2

**Analysis of Return Rate Comparison:**

*   TMDX has significantly outperformed the S&P 500, generating a cumulative return of 235.64% compared to the S&P 500's 72.50%. This is a considerable outperformance.
*   The "divergence" metrics help quantify this outperformance. The current divergence of 128.7 indicates the substantial lead TMDX holds over the S&P 500 in cumulative returns.
*   The relative divergence of 62.2 suggests that the current divergence is in the middle of its historical range (between the max and min divergence values). This means that while the outperformance is significant, it's not at its absolute peak compared to its own historical fluctuations.

**Alpha, Beta Analysis**

| Year       | CAGR   | MDD   | Alpha  | Beta | Cap(B) |
|------------|--------|-------|--------|------|--------|
| 2020-2022  | 94.0%  | 60.2% | 96.0%  | 1.3  | 2.1    |
| 2021-2023  | 65.0%  | 60.2% | 64.0%  | 1.7  | 2.7    |
| 2022-2024  | 130.0% | 51.7% | 111.0% | 1.8  | 2.1    |
| 2023-2025  | 120.0% | 53.4% | 58.0%  | 1.4  | 4.1    |

**Analysis of Alpha/Beta:**

*   **CAGR (Compound Annual Growth Rate):** TMDX has demonstrated very strong growth rates across all periods.
*   **MDD (Maximum Drawdown):**  The MDD figures show the potential downside risk. TMDX carries a high MDD.
*   **Alpha:** Consistently high alpha values across all periods indicate that TMDX has generated significant returns above what would be expected based on market movements alone.  This points to strong stock-specific factors driving performance.
*   **Beta:** Beta values ranging from 1.3 to 1.8 suggest that TMDX's price is more volatile than the overall market (S&P 500).  It tends to amplify market movements.
*   **Cap(B):** Market capitalization in billions of dollars.

**2) Recent Stock Price Fluctuations**

*   **Close:** 137.57
*   **Last-market:**
    *   Price: 137.07
    *   PreviousClose: 137.57
    *   Change: -0.36
*   **5-day SMA:** 131.30
*   **20-day SMA:** 126.82
*   **60-day SMA:** 127.70

**Analysis of Price Fluctuations:**

*   The stock price has closed slightly lower than its previous close.
*   The 5-day SMA is higher than both the 20-day and 60-day SMAs.  This suggests a short-term upward trend. However, the 20-day and 60-day SMAs are relatively close, indicating that the medium-term trend has been flatter or more sideways.

**3) Index Indicators Analysis**

*   **MRI (Market Risk Indicator):** 0.7 (Medium Investment)
*   **RSI:** 73.87 (Approaching Overbought)
*   **PPO:** 1.07
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.70)
*   **Recent (20 days) relative divergence change:** -3.1 (short-term decline)
*   **Expected Return (%):** 56.4%

**Analysis of Indicators:**

*   **MRI:** A rating of 0.7 suggests a medium level of investment risk.
*   **RSI:** An RSI of 73.87 is approaching the overbought territory (typically above 70), which *could* indicate a potential pullback or consolidation in the near term.
*   **PPO:** The PPO (Percentage Price Oscillator) indicates the stock is in an uptrend and confirms short-term momentum.
*   **Hybrid Signal:** The hybrid signal suggests a cautious approach, recommending buying 80% of cash and one share due to the moderate risk.
*   **Divergence Change:** The negative change in relative divergence over the past 20 days indicates a short-term decline in relative performance.
*   **Expected Return:** A projected 56.4% return suggests a bullish outlook for TMDX over the long term (2+ years).

**4) Recent News & Significant Events**

*   **[2026-01-09] 3 MedTech Stocks That Crushed the S&P 500 Over the Past Year:** This reinforces the strong recent performance of TMDX.
*   **[2026-01-07] Does TransMedics (TMDX) Logistics Integration Reframe Its Risk Reward Profile In Organ Transplantation?:** This article suggests that recent logistical changes could impact the company's risk-reward profile.
*   **[2025-12-17] TransMedics Group (NASDAQ:TMDX) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says:** Positive analyst sentiment suggesting potential upside.
*   **[2025-10-30] TMDX Stock Falls Despite Q3 Earnings Beat Estimates, Revenues Up Y/Y:**  Highlights that even positive earnings news can be followed by a stock price decline.  Suggests potential overvaluation or external market factors.
*   **[2025-12-22] TransMedics stock could see upside from heart trial, Piper Sandler says:** Positive sentiment related to a heart trial.
*   **[2025-12-23] TransMedics: A Stagnant Monopoly Facing Regulatory Pressure (NASDAQ:TMDX):** This article presents a more cautious view, raising concerns about regulatory challenges and potential stagnation.

**4-2) Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 1.67 (~Buy)
*   **Opinions:** 11
*   **Target Price (avg/high/low):** 144.73 / 170.00 / 114.00

**Analysis of Analyst Opinions:**

*   The overwhelming consensus among analysts is to "Buy" TMDX.
*   The average target price of $144.73 suggests a potential upside from the current price. However, note the range between the high and low targets is substantial.

**5) Comprehensive Analysis**

TransMedics Group Inc. (TMDX) has demonstrated significant outperformance compared to the S&P 500, with a cumulative return of 235.64%. Its high alpha confirms strong stock-specific factors are driving its performance. Recent news highlights both positive catalysts (analyst upgrades, heart trial potential) and potential concerns (regulatory pressure). The short-term outlook is mixed, with the RSI approaching overbought levels and a slight decline in relative divergence. However, the long-term expected return of 56.4% is highly encouraging.

The analyst consensus is a buy rating. A price decrease after positive Q3 earnings suggests caution. Logistics integration could significantly change the company's outlook. In summary, while TMDX has demonstrated very strong growth and has positive analyst sentiment, investors should acknowledge the potential regulatory hurdles and stagnation risks described in the Seeking Alpha article and be prepared for potentially high volatility given the high beta and MDD.



**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.